Esketamine Nasal Spray Market Size & Share, by Type (General Anaesthetics, Treatment-Resistant Depression); Application (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); Patient (Adult, Pediatric, Geriatric); Prescription (Over the Counters, Prescription) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5318
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Companies Dominating the Esketamine Nasal Spray Market

top-features-companies
    • Eli Lilly & Company
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bristol Myers Squibb Company
    • Novartis International AG
    • Bausch Health Companies Inc.
    • Validus Pharmaceuticals LLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Merck KGaA
    • Endo International Plc
    • MedKoo Biosciences, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • The Massachusetts General Brigham (MGB) led a new study that matched subanesthetic intravenous ketamine to electroconvulsive treatment (ECT) for the therapy of non-psychotic, treatment-resistant depression. The outcomes are released in the New England Journal of Medicine. In a clinical trial of 403 patients investigators discovered that 55 percent of those who got ketamine therapy suffered a constant betterment in depressive symptoms without major adverse impacts.
  • Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) confirmed that they have come into a conclusive planning agreement according to which Otsuka will obtain Mindset for approximately CAD 80 million in an all-cash deal. This agreement has been performed through Otsuka America, Inc. (OAI), a wholly-owned subsidiary of Otsuka. The Otsuka and Mindset boards of directors have accepted the deal. The purchase is anticipated to be completed during the fourth quarter of 2023, subject to needed techniques.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5318
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing cases of depression in people worldwide will majorly drive the market growth of the esketamine nasal spray market.

The market size of the esketamine nasal spray market is expected to get a CAGR of approximately 7% over the forecast period, i.e., 2024-2036.

The major players in the market are Eli Lilly & Company, Bristol Myers Squibb Company, Novartis International AG, Bausch Health Companies Inc., Validus Pharmaceuticals LLC, Pfizer Inc., AbbVie Inc., Merck KGaA, Endo International Plc, MedKoo Biosciences, Inc., Janssen Global Services, LLC, Otsuka Pharmaceutical Co., Ltd., Biogen Inc., Sage Therapeutics, Inc.

The treatment-resistant depression segment is anticipated to reap the largest market size with almost 63% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying